Brian J. McMahon, MD; Dana L. Bruden, MS; Kenneth M. Petersen, MD; Lisa R. Bulkow, MS; Alan J. Parkinson, PhD; Omana Nainan, PhD; Marina Khristova, PhD, DSc; Carolyn Zanis, BS; Helen Peters, BS; Harold S. Margolis, MD
Acknowledgments: The authors acknowledge the support they received from the many Community Health Aides in the study villages and the nurses at the Arctic Investigations Program and the Alaska Native Medical Center who over the years gave their valuable time to the study.
Grant Support: Partial support through the Alaska Native Tribal Health Consortium from the Division of Viral Hepatitis, National Centers for Infectious Diseases, Centers for Disease Control and Prevention Cooperative Agreement CA #U50/CCU022279. Merck & Co., Inc., West Point, Pennsylvania, supplied the vaccine and partially funded transportation during the first 10 years of follow-up through an unrestricted grant.
Potential Financial Conflicts of Interest: Grants received : B.J. McMahon (Merck Pharmaceuticals); Stock ownership or options (other than mutual funds): A.J. Parkinson (Merck & Co., Inc.).
Requests for Single Reprints: Brian J. McMahon, MD, Arctic Investigations Program, Centers for Disease Control and Prevention, 4055 Tudor Center Drive, Anchorage, AK 99508; e-mail, email@example.com.
Current Author Addresses: Dr. McMahon, Ms. Bruden, Ms. Bulkow, Dr. Parkinson, Ms. Zanis, and Ms. Peters: Arctic Investigations Program, Centers for Disease Control and Prevention, 4055 Tudor Center Drive, Anchorage, AK 99508.
Dr. Peterson: 13101 Floral Lane, Anchorage, AK 99516.
Drs. Nainan, Khristova, and Margolis: Viral Hepatitis Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333.
Author Contributions: Conception and design: B.J. McMahon, L.R. Bulkow, A.J. Parkinson.
Analysis and interpretation of the data: B.J. McMahon, D.L. Bruden, K.M. Petersen, L.R. Bulkow, M. Khristova.
Drafting of the article: B.J. McMahon, A.J. Parkinson, O. Nainan, M. Khristova.
Critical revision of the article for important intellectual content: B.J. McMahon, D.L. Bruden, K.M. Petersen, L.R. Bulkow, O. Nainan, H.S. Margolis.
Final approval of the article: B.J. McMahon, A.J. Parkinson, C. Zanis, H.V. Peters, H.S. Margolis.
Provision of study materials: K.M. Petersen, C. Zanis, H.V. Peters.
Statistical expertise: D.L. Bruden, L.R. Bulkow.
Obtaining of funding: H.S. Margolis.
Administrative, technical, or logistic support: O. Nainan, H.S. Margolis.
Collection and assembly of data: O. Nainan, M. Khristova, C. Zanis, H.V. Peters, H.S. Margolis.
McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up. Ann Intern Med. 2005;142:333-341. doi: 10.7326/0003-4819-142-5-200503010-00008
Download citation file:
Published: Ann Intern Med. 2005;142(5):333-341.
Although administration of hepatitis B vaccine for infants is routine practice in many countries, we do not know whether the protection that this vaccine offers lasts beyond 10 years. Such information is essential to develop policies about booster vaccination.
Of 841 Alaska Natives who received 3 doses of hepatitis B vaccination during 1981–1982 and were followed for 15 years, 84% had protective levels of antibody to hepatitis B surface antigen that indicated continued protection. The greatest decline in antibody levels occurred in people who received vaccine before 4 years of age. Definite asymptomatic breakthrough infections occurred in 16 participants.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Viral Hepatitis, Vaccines/Immunization, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only